Can a new drug help PAH patients breathe easier during exercise?
NCT ID NCT06409026
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the drug sotatercept, given for 36 weeks, improves how the heart and lungs work during exercise in people with pulmonary arterial hypertension (PAH). Thirty adults with PAH received injections of sotatercept. Researchers measured heart pressure, blood flow, and oxygen use during exercise to see if the drug helps patients feel better and move more easily.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sotatercept
What this could lead to
If successful, this could show that sotatercept improves exercise capacity and quality of life for people with pulmonary arterial hypertension.
What could go wrong
This is a small, completed Phase 4 trial with only 30 participants, so results may not apply to all patients. The drug may not show meaningful improvement in exercise outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States